Ticagrelor

CAS 274693-27-5 47 current records 1 historicalSmall Molecule

Who holds supplier records for Ticagrelor? 47 organisations hold a current record for Ticagrelor: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 29 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (25), China (14), Slovenia (2), Netherlands (1) and 2 other countries (2); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Ticagrelor: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/ticagrelor

Reading the evidence

  • 47 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 26 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Ticagrelor expires 27 Jul 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (47)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Ticagrelor. Country is the organisation's recorded country, not necessarily the manufacturing site.

India25China14Slovenia2Netherlands1Poland1Israel1Country not recorded for 3
Need Ticagrelor sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (29)

Certificates of Suitability on the EDQM register for Ticagrelor, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 34 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
ZHEJIANG SYNCOTIDE BIO-PHARMACEUTICAL CO., LTD. ShaoxingCN
CEP 2023-374 - Rev 01
Ticagrelor
Oct 2026Inspected Oct 2024
Belgium
TAPI NL B.V. AmsterdamNL
CEP 2021-225 - Rev 02
Ticagrelor
Sept 2026—
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2021-408 - Rev 02
Ticagrelor
Aug 2026—
VIYASH SCIENTIFIC LIMITED HyderabadIN
CEP 2022-274 - Rev 01
Ticagrelor
Jul 2026—
MSN ORGANICS PRIVATE LIMITED Bibinagar VillageIN
CEP 2021-027 - Rev 02
Ticagrelor, Form II, Micronised and Non-micronised
Jun 2026—
HONOUR LAB LIMITED HyderabadIN
CEP 2025-583 - Rev 00
Ticagrelor, Process-II
May 2026—
ALIVUS LIFE SCIENCES LIMITED MumbaiIN
CEP 2022-128 - Rev 02
Ticagrelor
May 2026—
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. TaizhouCN
CEP 2025-604 - Rev 00
Ticagrelor, Polymorphic Form II (Process A)
Mar 2026Inspected Jan 2024
Hungary
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. Taizhou CityCN
CEP 2024-020 - Rev 00
Ticagrelor
Feb 2026—
DIVI'S LABORATORIES LIMITED HyderabadIN
CEP 2022-072 - Rev 01
Ticagrelor
Feb 2026—
Changzhou Pharmaceutical Factory ChangzhouCN
CEP 2021-333 - Rev 02
Ticagrelor
Dec 2025Inspected Apr 2025
Italy
ZAKŁADY FARMACEUTYCZNE POLPHARMA S.A. Starogard GdańskiPL
CEP 2020-338 - Rev 04
Ticagrelor, Standard, micronised
Nov 2025Inspected Jul 2026
Poland
MACLEODS PHARMACEUTICALS LIMITED MumbaiIN
CEP 2023-368 - Rev 00
Ticagrelor
Oct 2025—
JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. YichunCN
CEP 2021-303 - Rev 01
Ticagrelor
Sept 2025—
MANKIND PHARMA LIMITED New DelhiIN
CEP 2022-067 - Rev 01
Ticagrelor
Jun 2025—
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
CEP 2023-397 - Rev 00
Ticagrelor
Apr 2025—
INTAS PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2022-333 - Rev 01
Ticagrelor, Form II, micronised
Jan 2025—
MICRO LABS LIMITED BengaluruIN
CEP 2021-173 - Rev 01
Ticagrelor
Dec 2024—
LEE PHARMA LIMITED HyderabadIN
CEP 2023-140 - Rev 00
Ticagrelor, Form II (micronised)
Nov 2024—
ZHEJIANG JIANGBEI NANHAI PHARMACEUTICAL CO., LTD Linhai CityCN
CEP 2023-011 - Rev 00
Ticagrelor
Sept 2024Inspected Oct 2025
France
CTX LIFESCIENCES PVT. LIMITED SuratIN
CEP 2023-071 - Rev 00
Ticagrelor
Sept 2024—
USV PRIVATE LIMITED MumbaiIN
CEP 2023-128 - Rev 00
Ticagrelor, Micronised
Jul 2024—
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Shenzhen CityCN
CEP 2022-491 - Rev 00
Ticagrelor
Jun 2024—
SUZHOU LIXIN PHARMACEUTICAL CO., LTD. SuzhouCN
CEP 2022-312 - Rev 00
Ticagrelor
May 2024Inspected Aug 2023
France, outside 3-year window
PHARMARESOURCES (KAIYUAN) COMPANY LIMITED Kaiyuan CityCN
CEP 2021-362 - Rev 00
Ticagrelor
Apr 2024—
KRKA, d.d., Novo mesto Novo mestoSI
CEP 2022-437 - Rev 00
Ticagrelor, Micronized
Mar 2024Inspected Jul 2025
Slovenia
SHAOXING JINGXIN PHARMACEUTICAL CO., LTD. ShangyuCN
CEP 2022-187 - Rev 01
Ticagrelor
Jan 2024—
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
CEP 2020-331 - Rev 00
Ticagrelor
Nov 2023—
ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. Taizhou CityCN
R0-CEP 2021-348 - Rev 00
Ticagrelor
Jul 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Ticagrelor are no longer active. These show a past filing, not current supply.

Show all 1 historical record

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (38 listed products contain Ticagrelor). The latest listed patent expires 27 Jul 2036. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Ticagrelor is an oral antiplatelet agent that belongs to the class of cyclopentyltriazolopyrimidines, used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome or myocardial infarction. It works by reversibly inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.

Chemical identity

IUPAC name
(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Canonical SMILES
CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
InChIKey
OEKWJQXRCDYSHL-FNOIDJSQSA-N
Synonyms
Brilinta API, ar-c126532xx, azd-6140, azd6140, brilinta, brilique, possia

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
P2Y12 Platelet Inhibitor
Mechanism of action
Cytochrome P450 3A4 Inhibitors; P-Glycoprotein Inhibitors; P2Y12 Receptor Antagonists
Physiologic effect
Decreased Platelet Aggregation

Therapeutic areas

Cardiovascular diseasesThrombosis

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Ticagrelor?

47 organisations hold an active US FDA Type II Drug Master File or a CEP for Ticagrelor: CHANGZHOU PHARMACEUTICAL FACTORY (China), HONOUR LAB LTD (India), MSN Organics Private Limited (India), Alembic Pharmaceuticals Limited (India), Divis Laboratories (India), Dr. Reddy's Laboratories Ltd. (India), Jiangxi Synergy Pharmaceutical Co., Ltd (China) and LEE PHARMA LTD (India), and 39 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Ticagrelor Drug Master Files are active?

CHANGZHOU PHARMACEUTICAL FACTORY (DMF 28984, 34835), HONOUR LAB LTD (DMF 28879, 41833), MSN Organics Private Limited (DMF 28938, 34699), Alembic Pharmaceuticals Limited (DMF 28899), Divis Laboratories (DMF 36701), Dr. Reddy's Laboratories Ltd. (DMF 28446), Jiangxi Synergy Pharmaceutical Co., Ltd (DMF 31620) and LEE PHARMA LTD (DMF 41989) and 29 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Ticagrelor records mean?

1 organisation has only inactive Type II DMFs for Ticagrelor. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Ticagrelor have a European Certificate of Suitability?

Yes. 29 organisations hold a valid CEP for Ticagrelor on the EDQM register, including ZHEJIANG SYNCOTIDE BIO-PHARMACEUTICAL CO., LTD. Shaoxing (CN), TAPI NL B.V. Amsterdam (NL), ALEMBIC PHARMACEUTICALS LIMITED Vadodara (IN), VIYASH SCIENTIFIC LIMITED Hyderabad (IN), MSN ORGANICS PRIVATE LIMITED Bibinagar Village (IN) and HONOUR LAB LIMITED Hyderabad (IN) and 23 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Ticagrelor?

Yes. The latest patent listed for an approved US product containing Ticagrelor expires 27 Jul 2036, across 38 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Ticagrelor supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Ticagrelor?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.